Immunotherapy for the Treatment of Drug Abuse. Pharmacol Ther. 2005; 108 :76–85.Kosten T, Owens M. Immunotherapy for the treatment of drug abuse. Pharmacol Ther. 2005:76–85.Kosten T, Owens M. Immunotherapy for the treatment of drug abuse. Pharmacology and Therapeutics. 2005:76–85....
Current medications for substance use disorders have many limitations s... X Shen,TR Kosten - 《Other》 被引量: 0发表: 2011年 Immunotherapy for the treatment of drug abuse Antibody therapy (as either active or passive immunization) is designed primarily to prevent drugs of abuse from entering ...
Immunotherapy for the treatment of drug abuse NicotineAntibody therapy (as either active or passive immunization) is designed primarily to prevent drugs of abuse from entering the central nervous system ... TKM Owens - 《Pharmacology & Therapeutics》 被引量: 166发表: 2005年 Vaccine for treating ni...
Immunotherapy could therefore have a place in the treatment ofsubstance abusein the future. This would be particularly useful as adjunctive therapy for specific patient groups, for example for pregnant drug abusers and during vulnerable periods after detoxification, where the risk of relapse is great....
Furthermore, we evaluated the potential of PD-L1 as a diagnostic marker for various diseases and discussed the possibility of repurposing ICBs initially developed for cancer treatment to treat other diseases using drug repositioning strategies. Non-canonical pathway of PD-L1/PD-1 signaling Upon ...
"We are excited to offer a new treatment option for patients with locally advanced cervical cancer who have been treated with chemoradiotherapy as standard of care," said Lee Min-hee, executive vice president of MSD Korea's Anti-Cancer Business Division. "This approval is the second indication ...
In this article, recent research studies in the field of cocaine addiction are reviewed, with an eye toward emergent options for treatment innovation. Part... Panikkar,Gopakumar P. - 《Substance Abuse》 被引量: 23发表: 1999年 Is immunotherapy an opportunity for effective treatment of drug addic...
On 30th August 2017, tisagenlecleucel became the first chimeric antigen receptor (CAR)-T-cell therapy to be approved by the FDA. This approval has important implications for health-care systems because the use of this promising treatment presents considerable logistical, toxicological, and financial...
The long-term objectives for the applicant are to better understand the neurolological and metabolic consequences of phencyclidine (PCP) abuse and to develop immunotherapeutic methods for the treatment of drug abuse. The first objective is designed to test the hypothesis that PCP metabolites can lead...
The invention relates to a treatment of human individuals suffering from food allergy. The treatment involves a specifically modified food allergen and is based on immunotherapy. Th